Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib

Martina Tilio, Valentina Gambini, Junbiao Wang, Chiara Garulli, Cristina Kalogris, Cristina Andreani, Caterina Bartolacci, Maria Elexpuru Zabaleta, Lucia Pietrella, Albana Hysi, Manuela Iezzi, Barbara Belletti, Fiorenza Orlando, Mauro Provinciali, Roberta Galeazzi, Cristina Marchini, Augusto Amici

Research output: Contribution to journalArticle

Abstract

HER2 tyrosine kinase receptor is a validated target in breast cancer therapy. However, increasing evidence points to a major role of Δ16HER2 splice variant commonly coexpressed with HER2 and identified as a clinically important HER2 molecular alteration promoting aggressive metastatic breast cancer. Consistently, mice transgenic for the human Δ16HER2 isoform (Δ16HER2 mice) develop invasive mammary carcinomas with early onset and 100% penetrance. The present study provides preclinical evidence that Δ16HER2 expression confers de novo resistance to standard anti-HER2-therapies such as Lapatinib and acquired resistance to the selective Src inhibitor Saracatinib in breast cancer. Of note, Dacomitinib, an irreversible small molecule pan-HER inhibitor, was able to completely suppress Δ16HER2-driven breast carcinogenesis. Thus, only Dacomitinib may offer benefit in this molecularly defined patient subset by irreversibly inhibiting Δ16HER2 activation.

Original languageEnglish
Pages (from-to)76-84
Number of pages9
JournalCancer Letters
Volume381
Issue number1
DOIs
Publication statusPublished - Oct 10 2016

Fingerprint

Breast Neoplasms
Penetrance
Receptor Protein-Tyrosine Kinases
Transgenic Mice
Protein Isoforms
Carcinogenesis
Breast
lapatinib
Therapeutics
PF 00299804
saracatinib

Keywords

  • Breast cancer
  • Drug resistances
  • HER2 isoform
  • Targeted therapies
  • Δ16HER2 mice

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib. / Tilio, Martina; Gambini, Valentina; Wang, Junbiao; Garulli, Chiara; Kalogris, Cristina; Andreani, Cristina; Bartolacci, Caterina; Elexpuru Zabaleta, Maria; Pietrella, Lucia; Hysi, Albana; Iezzi, Manuela; Belletti, Barbara; Orlando, Fiorenza; Provinciali, Mauro; Galeazzi, Roberta; Marchini, Cristina; Amici, Augusto.

In: Cancer Letters, Vol. 381, No. 1, 10.10.2016, p. 76-84.

Research output: Contribution to journalArticle

Tilio, M, Gambini, V, Wang, J, Garulli, C, Kalogris, C, Andreani, C, Bartolacci, C, Elexpuru Zabaleta, M, Pietrella, L, Hysi, A, Iezzi, M, Belletti, B, Orlando, F, Provinciali, M, Galeazzi, R, Marchini, C & Amici, A 2016, 'Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib', Cancer Letters, vol. 381, no. 1, pp. 76-84. https://doi.org/10.1016/j.canlet.2016.07.028
Tilio, Martina ; Gambini, Valentina ; Wang, Junbiao ; Garulli, Chiara ; Kalogris, Cristina ; Andreani, Cristina ; Bartolacci, Caterina ; Elexpuru Zabaleta, Maria ; Pietrella, Lucia ; Hysi, Albana ; Iezzi, Manuela ; Belletti, Barbara ; Orlando, Fiorenza ; Provinciali, Mauro ; Galeazzi, Roberta ; Marchini, Cristina ; Amici, Augusto. / Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib. In: Cancer Letters. 2016 ; Vol. 381, No. 1. pp. 76-84.
@article{7f206d1f08194679af3d65be43e77975,
title = "Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib",
abstract = "HER2 tyrosine kinase receptor is a validated target in breast cancer therapy. However, increasing evidence points to a major role of Δ16HER2 splice variant commonly coexpressed with HER2 and identified as a clinically important HER2 molecular alteration promoting aggressive metastatic breast cancer. Consistently, mice transgenic for the human Δ16HER2 isoform (Δ16HER2 mice) develop invasive mammary carcinomas with early onset and 100{\%} penetrance. The present study provides preclinical evidence that Δ16HER2 expression confers de novo resistance to standard anti-HER2-therapies such as Lapatinib and acquired resistance to the selective Src inhibitor Saracatinib in breast cancer. Of note, Dacomitinib, an irreversible small molecule pan-HER inhibitor, was able to completely suppress Δ16HER2-driven breast carcinogenesis. Thus, only Dacomitinib may offer benefit in this molecularly defined patient subset by irreversibly inhibiting Δ16HER2 activation.",
keywords = "Breast cancer, Drug resistances, HER2 isoform, Targeted therapies, Δ16HER2 mice",
author = "Martina Tilio and Valentina Gambini and Junbiao Wang and Chiara Garulli and Cristina Kalogris and Cristina Andreani and Caterina Bartolacci and {Elexpuru Zabaleta}, Maria and Lucia Pietrella and Albana Hysi and Manuela Iezzi and Barbara Belletti and Fiorenza Orlando and Mauro Provinciali and Roberta Galeazzi and Cristina Marchini and Augusto Amici",
year = "2016",
month = "10",
day = "10",
doi = "10.1016/j.canlet.2016.07.028",
language = "English",
volume = "381",
pages = "76--84",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib

AU - Tilio, Martina

AU - Gambini, Valentina

AU - Wang, Junbiao

AU - Garulli, Chiara

AU - Kalogris, Cristina

AU - Andreani, Cristina

AU - Bartolacci, Caterina

AU - Elexpuru Zabaleta, Maria

AU - Pietrella, Lucia

AU - Hysi, Albana

AU - Iezzi, Manuela

AU - Belletti, Barbara

AU - Orlando, Fiorenza

AU - Provinciali, Mauro

AU - Galeazzi, Roberta

AU - Marchini, Cristina

AU - Amici, Augusto

PY - 2016/10/10

Y1 - 2016/10/10

N2 - HER2 tyrosine kinase receptor is a validated target in breast cancer therapy. However, increasing evidence points to a major role of Δ16HER2 splice variant commonly coexpressed with HER2 and identified as a clinically important HER2 molecular alteration promoting aggressive metastatic breast cancer. Consistently, mice transgenic for the human Δ16HER2 isoform (Δ16HER2 mice) develop invasive mammary carcinomas with early onset and 100% penetrance. The present study provides preclinical evidence that Δ16HER2 expression confers de novo resistance to standard anti-HER2-therapies such as Lapatinib and acquired resistance to the selective Src inhibitor Saracatinib in breast cancer. Of note, Dacomitinib, an irreversible small molecule pan-HER inhibitor, was able to completely suppress Δ16HER2-driven breast carcinogenesis. Thus, only Dacomitinib may offer benefit in this molecularly defined patient subset by irreversibly inhibiting Δ16HER2 activation.

AB - HER2 tyrosine kinase receptor is a validated target in breast cancer therapy. However, increasing evidence points to a major role of Δ16HER2 splice variant commonly coexpressed with HER2 and identified as a clinically important HER2 molecular alteration promoting aggressive metastatic breast cancer. Consistently, mice transgenic for the human Δ16HER2 isoform (Δ16HER2 mice) develop invasive mammary carcinomas with early onset and 100% penetrance. The present study provides preclinical evidence that Δ16HER2 expression confers de novo resistance to standard anti-HER2-therapies such as Lapatinib and acquired resistance to the selective Src inhibitor Saracatinib in breast cancer. Of note, Dacomitinib, an irreversible small molecule pan-HER inhibitor, was able to completely suppress Δ16HER2-driven breast carcinogenesis. Thus, only Dacomitinib may offer benefit in this molecularly defined patient subset by irreversibly inhibiting Δ16HER2 activation.

KW - Breast cancer

KW - Drug resistances

KW - HER2 isoform

KW - Targeted therapies

KW - Δ16HER2 mice

UR - http://www.scopus.com/inward/record.url?scp=84979887689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979887689&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2016.07.028

DO - 10.1016/j.canlet.2016.07.028

M3 - Article

VL - 381

SP - 76

EP - 84

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -